Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells.

Sabit H, Samy MB, Said OA, El-Zawahri MM.

Genet Res Int. 2016;2016:8348450. Epub 2016 Oct 24.

2.

Automated prediction of HIV drug resistance from genotype data.

Shen C, Yu X, Harrison RW, Weber IT.

BMC Bioinformatics. 2016 Aug 31;17 Suppl 8:278. doi: 10.1186/s12859-016-1114-6.

3.

Genetic Consequences of Antiviral Therapy on HIV-1.

Arenas M.

Comput Math Methods Med. 2015;2015:395826. doi: 10.1155/2015/395826. Epub 2015 Jun 10. Review.

4.

Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.

Tang YW, Ou CY.

Emerg Microbes Infect. 2012 Aug;1(8):e19. doi: 10.1038/emi.2012.15. Epub 2012 Aug 22. Review.

5.

Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.

O'Rourke SM, Sutthent R, Phung P, Mesa KA, Frigon NL, To B, Horthongkham N, Limoli K, Wrin T, Berman PW.

PLoS One. 2015 Mar 20;10(3):e0119608. doi: 10.1371/journal.pone.0119608. eCollection 2015.

6.

Cost-effectiveness of genotype testing for primary resistance in Brazil.

Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YM, Girouard MP, Sax PE, Struchiner CJ, Paltiel AD.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):152-61. doi: 10.1097/QAI.0000000000000426.

7.

The impact of clinical, demographic and risk factors on rates of HIV transmission: a population-based phylogenetic analysis in British Columbia, Canada.

Poon AF, Joy JB, Woods CK, Shurgold S, Colley G, Brumme CJ, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2015 Mar 15;211(6):926-35. doi: 10.1093/infdis/jiu560. Epub 2014 Oct 13.

8.

Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.

Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JS, Harrigan PR, Swenson LC.

Clin Infect Dis. 2014 Apr;58(8):1165-73. doi: 10.1093/cid/ciu019. Epub 2014 Jan 14.

9.
10.

Understanding resistance to combination chemotherapy.

Pritchard JR, Lauffenburger DA, Hemann MT.

Drug Resist Updat. 2012 Oct;15(5-6):249-57. doi: 10.1016/j.drup.2012.10.003. Epub 2012 Nov 17. Review.

11.

Prevalence of and viral outcomes associated with primary HIV-1 drug resistance.

Buskin SE, Zhang S, Thibault CS.

Open AIDS J. 2012;6:181-7. doi: 10.2174/1874613601206010181. Epub 2012 Sep 7.

12.

Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1.

Banks L, Gholamin S, White E, Zijenah L, Katzenstein DA.

J AIDS Clin Res. 2012 Feb;3(2):141-147.

13.

Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.

Puertas MC, Buzón MJ, Ballestero M, Van Den Eede P, Clotet B, Prado JG, Martinez-Picado J.

J Clin Microbiol. 2012 Dec;50(12):3909-16. doi: 10.1128/JCM.01636-12. Epub 2012 Sep 26.

14.

Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India.

Sinha S, Ahmad H, Shekhar RC, Kumar N, Dar L, Samantaray JC, Sharma SK, Bhargava A, Pandey RM, Mitsuyasu RL, Fahey JL.

AIDS Res Treat. 2012;2012:905823. doi: 10.1155/2012/905823. Epub 2012 Mar 15.

15.

A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Shafer RW, Dupnik K, Winters MA, Eshleman SH.

HIV Seq Compend. 2001;2001:1-51. No abstract available.

16.

Clinical management of HIV drug resistance.

Cortez KJ, Maldarelli F.

Viruses. 2011 Apr;3(4):347-78. doi: 10.3390/v3040347. Epub 2011 Apr 14. Review.

17.

Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.

Emmadi R, Boonyaratanakornkit JB, Selvarangan R, Shyamala V, Zimmer BL, Williams L, Bryant B, Schutzbank T, Schoonmaker MM, Amos Wilson JA, Hall L, Pancholi P, Bernard K.

J Mol Diagn. 2011 Nov;13(6):583-604. doi: 10.1016/j.jmoldx.2011.05.011. Epub 2011 Aug 25. Review.

18.

The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.

Hong SY, Nachega JB, Kelley K, Bertagnolio S, Marconi VC, Jordan MR.

Infect Disord Drug Targets. 2011 Apr;11(2):124-33. Review.

19.

"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.

Swenson LC, Pollock G, Wynhoven B, Mo T, Dong W, Hogg RS, Montaner JS, Harrigan PR.

PLoS One. 2011 Feb 24;6(2):e17402. doi: 10.1371/journal.pone.0017402.

20.

Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.

Fehr J, Glass TR, Louvel S, Hamy F, Hirsch HH, von Wyl V, Böni J, Yerly S, Bürgisser P, Cavassini M, Fux CA, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard HF, Battegay M, Bucher HC, Klimkait T; Swiss HIV Cohort Study..

J Transl Med. 2011 Jan 21;9:14. doi: 10.1186/1479-5876-9-14.

Supplemental Content

Support Center